AAGH America Great Health (PK)

Crown Marketing (OTCQB: CWNM) is pleased to announce that its subsidiary, Crown Nutraceuticals, has begun sales of its two popular diet products: Raspberry Ketones and Green Coffee Bean Extract.

"We're right on schedule," said Chris Francis, Director of Business Development. He continued, "We announced on April 24th that we would begin sales in thirty-days, and we beat it by nine days. Our aggressive media buy for online promotion will get us off to a fast start."

In discussing strategy, Francis stated, "Our buys will be carefully targeted to the most responsive demographics, on a rolling basis as the campaign develops." Francis surmised, "We suspect this will be young people, 22 to 35 year old college graduates residing in populous urban centers most susceptible to trend-like behavior. This tiered advertising campaign will allow the Company to make adjustments throughout the campaign to ensure that products are properly targeted to markets showing the greatest receptivity. "This isn't a one size fits all," continued Francis. We are well poised to press forward, with all diligent speed, into whichever market responds best."

About Crown Nutraceuticals:

Crown Nutraceuticals is engaged in the development, manufacturing and marketing of popular nutraceuticals and supplements.

The global nutraceuticals product market is massive -- reaching over $142.1 billion in 2011 and the industry is projected to reach $204.8 billion by 2017, with a projected annual growth rate of 6.3% from 2012 to 2017. Asia Pacific (including Japan) is expected to have the second largest market share after North America by 2017. Crown Nutraceutical's objective is to rapidly expand its business in the nutraceuticals and supplement market.

About Crown Marketing:

Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory along with precise mathematical formulas for precise and programmable diffusion delivery

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact: Charles Van Der Ross 347-491-0565